Tasigna (nilotinib)

News alerts, weekly reports and conference planners

Company:

Inhibikase, Novartis

Drug class:

Bcr-abl tyrosine kinase inhibitor

Related drugs:

BCR-ABL1 fusion	Chronic Myeloid Leukemia	BCR-ABL1 fusion	Chronic Myeloid Leukemia	nilotinib Sensitive: A1 - Approval nilotinib Sensitive : A1	nilotinib Sensitive: A1 - Approval nilotinib Sensitive : A1
BCR-ABL1 fusion	Acute Lymphocytic Leukemia	BCR-ABL1 fusion	Acute Lymphocytic Leukemia	nilotinib Sensitive: A2 - Guideline nilotinib Sensitive : A2	nilotinib Sensitive: A2 - Guideline nilotinib Sensitive : A2
BCR-ABL1 T315I	Acute Lymphocytic Leukemia	BCR-ABL1 T315I	Acute Lymphocytic Leukemia	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2
BCR-ABL1 T315I	Chronic Myeloid Leukemia	BCR-ABL1 T315I	Chronic Myeloid Leukemia	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2
No biomarker	Chronic Myeloid Leukemia	No biomarker	Chronic Myeloid Leukemia	nilotinib Sensitive: A2 - Guideline nilotinib Sensitive : A2	nilotinib Sensitive: A2 - Guideline nilotinib Sensitive : A2
BCR-ABL1 E255V	Acute Lymphocytic Leukemia	BCR-ABL1 E255V	Acute Lymphocytic Leukemia	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2
BCR-ABL1 G250E	Acute Lymphocytic Leukemia	BCR-ABL1 G250E	Acute Lymphocytic Leukemia	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2
BCR-ABL1 Y253H	Chronic Myeloid Leukemia	BCR-ABL1 Y253H	Chronic Myeloid Leukemia	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2
BCR-ABL1 E255K	Chronic Myeloid Leukemia	BCR-ABL1 E255K	Chronic Myeloid Leukemia	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2
BCR-ABL1 E255V	Chronic Myeloid Leukemia	BCR-ABL1 E255V	Chronic Myeloid Leukemia	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2
BCR-ABL1 F359V	Chronic Myeloid Leukemia	BCR-ABL1 F359V	Chronic Myeloid Leukemia	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2
BCR-ABL1 F359C	Chronic Myeloid Leukemia	BCR-ABL1 F359C	Chronic Myeloid Leukemia	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2
BCR-ABL1 F359I	Chronic Myeloid Leukemia	BCR-ABL1 F359I	Chronic Myeloid Leukemia	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2
BCR-ABL1 F317L	Chronic Myeloid Leukemia	BCR-ABL1 F317L	Chronic Myeloid Leukemia	nilotinib Sensitive: A2 - Guideline nilotinib Sensitive : A2	nilotinib Sensitive: A2 - Guideline nilotinib Sensitive : A2
BCR-ABL1 F317L	Acute Lymphocytic Leukemia	BCR-ABL1 F317L	Acute Lymphocytic Leukemia	nilotinib Sensitive: A2 - Guideline nilotinib Sensitive : A2	nilotinib Sensitive: A2 - Guideline nilotinib Sensitive : A2
BCR-ABL1 F359I	Acute Lymphocytic Leukemia	BCR-ABL1 F359I	Acute Lymphocytic Leukemia	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2
BCR-ABL1 F359C	Acute Lymphocytic Leukemia	BCR-ABL1 F359C	Acute Lymphocytic Leukemia	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2
BCR-ABL1 F359V	Acute Lymphocytic Leukemia	BCR-ABL1 F359V	Acute Lymphocytic Leukemia	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2
BCR-ABL1 E255K	Acute Lymphocytic Leukemia	BCR-ABL1 E255K	Acute Lymphocytic Leukemia	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2
BCR-ABL1 Y253H	Acute Lymphocytic Leukemia	BCR-ABL1 Y253H	Acute Lymphocytic Leukemia	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2	nilotinib Resistant: A2 - Guideline nilotinib Resistant : A2
KIT exon 13 mutation	Melanoma	KIT exon 13 mutation	Melanoma	nilotinib Sensitive: A2 - Guideline nilotinib Sensitive : A2	nilotinib Sensitive: A2 - Guideline nilotinib Sensitive : A2
No biomarker	Gastrointestinal Stromal Tumor	No biomarker	Gastrointestinal Stromal Tumor	nilotinib Sensitive: A2 - Guideline nilotinib Sensitive : A2	nilotinib Sensitive: A2 - Guideline nilotinib Sensitive : A2
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	nilotinib Sensitive: A2 - Guideline nilotinib Sensitive : A2	nilotinib Sensitive: A2 - Guideline nilotinib Sensitive : A2
No biomarker	Tenosynovial Giant Cell Tumor	No biomarker	Tenosynovial Giant Cell Tumor	nilotinib Sensitive: A2 - Guideline nilotinib Sensitive : A2	nilotinib Sensitive: A2 - Guideline nilotinib Sensitive : A2
KIT amplification	Melanoma	KIT amplification	Melanoma	nilotinib Sensitive: C2 – Inclusion Criteria nilotinib Sensitive : C2	nilotinib Sensitive: C2 – Inclusion Criteria nilotinib Sensitive : C2
KIT exon 11 mutation	Melanoma	KIT exon 11 mutation	Melanoma	nilotinib Sensitive: C2 – Inclusion Criteria nilotinib Sensitive : C2	nilotinib Sensitive: C2 – Inclusion Criteria nilotinib Sensitive : C2
ABL1 expression	Acute Myelogenous Leukemia	ABL1 expression	Acute Myelogenous Leukemia	nilotinib Sensitive: C3 – Early Trials nilotinib Sensitive : C3	nilotinib Sensitive: C3 – Early Trials nilotinib Sensitive : C3
BCR expression	Acute Myelogenous Leukemia	BCR expression	Acute Myelogenous Leukemia	nilotinib Sensitive: C3 – Early Trials nilotinib Sensitive : C3	nilotinib Sensitive: C3 – Early Trials nilotinib Sensitive : C3
KIT exon 11 mutation + KIT exon 17 mutation	Gastrointestinal Stromal Tumor	KIT exon 11 mutation + KIT exon 17 mutation	Gastrointestinal Stromal Tumor	nilotinib Sensitive: C3 – Early Trials nilotinib Sensitive : C3	nilotinib Sensitive: C3 – Early Trials nilotinib Sensitive : C3
BCR-ABL1 T315I	Chronic Myeloid Leukemia	BCR-ABL1 T315I	Chronic Myeloid Leukemia	dasatinib + nilotinib Resistant: C3 – Early Trials dasatinib + nilotinib Resistant : C3	dasatinib + nilotinib Resistant: C3 – Early Trials dasatinib + nilotinib Resistant : C3
BCR-ABL1 fusion	Chronic Myeloid Leukemia	BCR-ABL1 fusion	Chronic Myeloid Leukemia	venetoclax + nilotinib Sensitive: C3 – Early Trials venetoclax + nilotinib Sensitive : C3	venetoclax + nilotinib Sensitive: C3 – Early Trials venetoclax + nilotinib Sensitive : C3
KIT exon 11 mutation	Gastrointestinal Stromal Tumor	KIT exon 11 mutation	Gastrointestinal Stromal Tumor	nilotinib Sensitive: C3 – Early Trials nilotinib Sensitive : C3	nilotinib Sensitive: C3 – Early Trials nilotinib Sensitive : C3

Tasigna (nilotinib)

Associations
(66)

Associations
(66)

Tasigna (nilotinib)

Associations(66)

Associations(66)

Associations
(66)

Associations
(66)